Weight Loss Pills: How They Work, Safety, and History

How Weight Loss Pills Have Changed — and What That Means for Safety

How Weight Loss Pills Have Changed — and What That Means for Safety
iStock
Though recent data shows a meaningful decrease in the U.S. adult obesity rate (37 percent in 2025 compared with a record high of 39.9 percent in 2022), the need for obesity treatments is still high.

 Many people can lose weight by exercising more, eating less, and adding more fruits and vegetables to their diet, but multiple factors in addition to lifestyle changes play a role in managing obesity.

“[Obesity] is a lifelong disease that requires lifelong intervention, and even when people make lifestyle changes, they still have to fight against weight gain,” says Timothy Garvey, MD, a professor in the department of nutrition sciences and the director of the Diabetes Research Center at the University of Alabama in Birmingham. “Medications can stop the processes that cause this weight gain.”

The weight loss medications on the market today are generally approved for adults with obesity who have a body mass index (BMI) of 30 or higher, and adults with a BMI of 27 or higher who have at least one weight-related health problem, such as high blood pressure, sleep apnea, type 2 diabetes, and high cholesterol.

Early Weight Loss Drugs

Until recently, very few patients who met the above criteria took drugs to lose weight. One study collected prescription data from more than 2.2 million adults eligible for treatment with weight loss medications from 2009 to 2015.

 Part of the problem came down to safety concerns, particularly because so many of the first drugs used for weight loss decades ago had potentially life-threatening side effects.

As far back as the 1940s, cocktails of appetite suppressants known as “rainbow pills” were heavily marketed to American women.

The brightly colored capsules often contained amphetamines, diuretics, laxatives, and thyroid hormones to maximize weight loss. They were typically mixed with drugs like benzodiazepines, barbiturates, and antidepressants. By the 1960s, after those potent cocktails of drugs had caused dozens of deaths, the U.S. Food and Drug Administration (FDA) removed them from the market.

“None of these medications were tested in long-term trials prior to repurposing them for the treatment of obesity. This raises the risk that they will have side effects not recognized in short-term therapy,” says Frank Greenway, MD, the chief medical officer and a professor at the Pennington Biomedical Research Center at Louisiana State University in Baton Rouge.

In the 1990s, another untested weight loss cocktail nicknamed fen-phen started taking off.

This cocktail mixed the psychiatric drug fenfluramine, which boosts levels of the brain chemical serotonin and induces feelings of satiety, with the appetite suppressant phentermine. An older version of fenfluramine, marketed as Pondimin, was on the market for more than two decades, and a newer version called dexfenfluramine, marketed as Redux, was sold for about a year before both were recalled in 1997 because of concerns that the products caused heart valve defects.
An appetite suppressant called sibutramine, marketed as Meridia, was recalled by the FDA in 2010 after more than a decade on the market because of an increased risk of cardiovascular events and strokes.

 Next up, the prescription weight loss drug lorcaserin (Belviq) was recalled by the FDA over cancer concerns in 2020, after more than a decade on the market.

Tougher Drug Testing Requirements

After so many weight loss drugs were recalled because of dangerous side effects, in the late 1990s, the FDA recommended that new medications to treat obesity undergo yearlong clinical trials before approval.

All the medications approved in the last decade have a good track record of safety so far, says Adam Gilden, MD, an associate professor and obesity researcher at the University of Colorado School of Medicine in Aurora. These newer drugs either combine medicines that have good safety records when used individually or those that have been used for a long time to manage type 2 diabetes before gaining traction as obesity treatments.

“So, we can feel good that these medicines are safe,” Dr. Gilden says. “Also, every one of these medicines will be subjected to large post-marketing trials, which will further assess safety and longer-term efficacy.”

“I think it is a very exciting time for obesity medicine because we now have several effective treatments to choose from,” says Melanie Jay, MD, an obesity researcher and a professor at the New York University Grossman School of Medicine in New York City.

Weight Loss Drug Options

For many patients today, a decision about which weight loss medication to try may come down to several factors, including what other medications they take, which drugs are covered by insurance or are most affordable, and whether people prefer pills or injected medicines, Dr. Jay says.

“I advise people to speak to their physician to choose an initial medication and see how they respond,” Jay says. “It’s not uncommon to switch medications or have to add a second or third medication.”

Here’s what you need to know about the prescription weight loss drugs that are currently approved.

Tirzepatide (Zepbound)

This weekly injected medicine was approved by the FDA in 2023 to treat adults with obesity and overweight adults with at least one weight-related chronic health problem.

How it works: Tirzepatide mimics two hormones that regulate insulin secretion and digestion: glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is widely believed to be the most potent weight loss drug ever approved for sale: In the SURMOUNT-1 trial, participants using the highest dose lost an average of 22.5 percent of their body weight.

Common side effects: Nausea, diarrhea, vomiting, and constipation.

Interactions and risks: Rare but potentially dangerous reactions include severe gastrointestinal disease and acute injury to the pancreas, kidneys, or gallbladder.

Semaglutide (Wegovy)

Wegovy was approved by the FDA to treat adults with obesity as well as adults who are overweight and also have at least one weight-related chronic health problem. The weekly injected form of the medicine was approved in 2021, and the once-daily oral version was approved in 2025.

How it works: It’s another GLP-1 receptor agonist that mimics a hormone in the brain that regulates appetite.

Common side effects: Nausea, diarrhea, vomiting, constipation, stomach pain, headache, and fatigue.

Interactions and risks: It can’t be used in combination with liraglutide or other GLP-1 receptor agonists that are prescribed for type 2 diabetes. Like other drugs in this family of medicines, including tirzepatide and liraglutide, it carries an increased risk of pancreatitis and has been linked to thyroid tumors in animals.

Naltrexone-Bupropion (Contrave)

This oral drug was approved by the FDA in 2014.

How it works: It’s a combination of two drugs that are used to treat addiction and depression, and it suppresses appetite and makes people feel full sooner.

Common side effects: Constipation, dizziness, diarrhea, dry mouth, headache, increased blood pressure, elevated heart rate, insomnia, liver damage, nausea, and vomiting.

Interactions and risks: It shouldn’t be used by people with uncontrolled blood pressure, seizures, a history of anorexia or bulimia, people taking psychiatric drugs containing bupropion (Wellbutrin, Zyban), or individuals dependent on opioids or in withdrawal from drugs or alcohol. It can increase suicidal thoughts or actions.

Liraglutide (Saxenda)

This daily injected drug was approved by the FDA in 2014 for adults and in 2020 for children ages 12 and older with obesity.

How it works: It’s in a family of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking a hormone in the brain that regulates appetite and food consumption.

Common side effects: Nausea, diarrhea, constipation, abdominal pain, headache, and increased heart rate. Rare side effects include an increased risk of pancreatitis, and it’s been linked to thyroid tumors in animals.

Interactions and risks: In a smaller dose, liraglutide is used as a diabetes medication called Victoza, which should not be used in conjunction with Saxenda.

Phentermine-Topiramate (Qsymia)

This pill was approved by the FDA in 2012 for adults who are overweight or obese, and in 2022 for patients ages 12 and older with obesity.

How it works: This combination pill suppresses appetite and makes people feel full sooner.

Common side effects: Constipation, dizziness, dry mouth, tingling in hands and feet, brain fog or cognitive impairment, and difficulty sleeping.

Interactions and risks: It shouldn’t be used by people with glaucoma or hyperthyroidism, by women who are pregnant or breastfeeding, or by some individuals with a history of heart attack, stroke, heart rhythm disorders, kidney disease, or mood problems.

Orlistat (Xenical, Alli)

This pill was approved by the FDA in 1999 as a prescription weight loss drug (Xenical) and in 2007 at a lower dose for nonprescription use (Alli).

How it works: It works in the gut to limit the amount of fat absorbed from foods you eat.

Common side effects: Diarrhea, gas, stomach pain, and oily stool leakage.

Interactions and risks: It’s linked to rare cases of severe liver injury; dangerous interactions with cyclosporine, a drug to prevent organ transplant rejections; and the potential for malnutrition if patients don’t take a multivitamin.

 Orlistat has been shown to decrease the absorption of fat-soluble vitamins as well as some prescription medications, including Amiodarone (used to treat irregular heartbeats)and ciclosporin (used to treat inflammatory diseases like rheumatoid arthritis). Orlistat may also affect the dosage of warfarin, an anticoagulant.

What to Consider Before Taking Weight Loss Pills

Weight loss medications should not be used during pregnancy or while trying to conceive.

Those with kidney impairment and those at risk for kidney stones should discuss the risks and benefits of weight loss medication with a medical provider.

 So should those who have an eating disorder or are at risk.

Though it can sometimes be expensive or difficult to access support with lifestyle interventions, the most recent guidelines on treating obesity state that those taking weight loss medications should do their best to combine them with lifestyle changes. This includes a healthy diet, physical activity, and regular wellness check-ins with an obesity specialist.

The Takeaway

  • For many people with obesity who struggle to shed excess pounds, prescription weight loss drugs can help when lifestyle changes like calorie restriction and exercise aren’t enough.
  • So far, drugs approved within the past decade have proved safer than earlier weight loss drugs.
  • Before starting weight loss medication, discuss your options with a healthcare provider to learn about potential risks and side effects.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Witters D et al. Obesity Rate Declining in U.S. Gallup. October 28, 2025.
  2. Masood B et al. Causes of Obesity: A Review. Clinical Medicine. July 2023.
  3. Prescription Medications to Treat Overweight and Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. June 2024.
  4. Saxon DR et al. Anti-Obesity Medication Use in 2.2 Million Adults Across 8 Large Healthcare Organizations: 2009-2015. Obesity. October 11, 2019.
  5. Bray GA et al. An Historical Review of Steps and Missteps in the Discovery of Anti-Obesity Drugs. Endotext. July 10, 2022.
  6. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). U.S. Food and Drug Administration. February 6, 2018.
  7. FDA Requests the Withdrawal of the Weight-Loss Drug Belviq, Belviq Xr (Lorcaserin) From the Market. U.S. Food and Drug Administration. February 13, 2020.
  8. Colman E. Food and Drug Administration's Obesity Drug Guidance Document: A Short History. Circulation. May 1, 2012.
  9. FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration. November 8, 2023.
  10. Jastreboff A et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. June 4, 2022.
  11. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. U.S. Food and Drug Administration. March 8, 2024.
  12. Novo Nordisk A/S: Wegovy Pill Approved in the US as First Oral Glp-1 for Weight Management. Novo Nordisk. December 22, 2025.
  13. Approval Package for: 200063Orig1s000. Center for Drug Evaluation and Research. September 10, 2014.
  14. FDA Approves Weight Management Drug for Patients Aged 12 and Older. U.S. Food and Drug Administration. June 15, 2021.
  15. FDA Approves Treatment for Chronic Weight Management in Pediatric Patients Aged 12 Years and Older. U.S. Food and Drug Administration. June 27, 2022.
  16. Orlistat (Marketed as Alli and Xenical) Information. U.S. Food and Drug Administration. July 8, 2015.
  17. Munoz-Mantilla D. Top Weight Loss Medications. Obesity Medicine Association. July 29, 2025.
  18. Sauerwein K. Study Identifies Benefits, Risks Linked to Popular Weight-Loss Drugs. WashU Medicine. January 20, 2025.
  19. Chiappini S et al. Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals. July 11, 2023.
  20. WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity.  World Health Organization. December 1, 2025.
Sean-Hashmi-bio

Sean Hashmi, MD

Medical Reviewer

Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management at a prominent healthcare organization in Southern California, Dr. Hashmi oversees the development and implementation of cutting-edge nutritional programs and weight management strategies. With his innovative approach and unwavering commitment to providing evidence-based solutions, he is a highly sought-after speaker and a leader in his field.

Hashmi founded the nonprofit organization SelfPrinciple.org to provide accessible and accurate health, nutrition, and wellness information to the public. Through this platform, he shares the latest research findings, empowering individuals to make informed decisions about their well-being. Self Principle also supports children's education by providing scholarships, books, and supplies, so that students have the resources necessary to succeed academically and build a brighter future.

lisa-rapaport-bio

Lisa Rapaport

Author
Lisa Rapaport is a journalist with more than 20 years of experience on the health beat as a writer and editor. She holds a master’s degree from the UC Berkeley Graduate School of Journalism and spent a year as a Knight-Wallace journalism fellow at the University of Michigan. Her work has appeared in dozens of local and national media outlets, including Reuters, Bloomberg, WNYC, The Washington Post, Los Angeles Times, Scientific American, San Jose Mercury News, Oakland Tribune, Huffington Post, Yahoo! News, The Sacramento Bee, and The Buffalo News.